Methods for diagnosing cancer by measuring creatine kinase
AssigneeHorus Therapeutics, Inc.
InventorsZhen Zhang, Stephen D. Barnhill, Ramananda Madyastha, Hong Zhang
Life of this patent
Estimating the term…
Abstract
The diagnostic method of the present invention provides a method of diagnosing prostate cancer by measuring the concentration of prostate specific antigen and creatine kinase enzyme activity. A mathematical relationship between the two concentrations is then determined. If the prostate specific antigen concentration in the blood is normal or near normal and the creatine kinase enzyme value is lower than normal, than there is a high likelihood that the patient has prostate cancer. The present invention also includes the measurement of creatine kinase enzyme inhibitor in the serum of a patient to determine if the patient has a high likelihood of cancer.
Claims7
A method of screening for prostate cancer in a human or an animal comprising:
- measuring creatine kinase enzymatic activity in a sample from the human or animal and comparing the creatine kinase enzymatic activity to a normal control;
- and
- measuring prostate specific antigen in the sample and comparing the concentration of prostate specific antigen to a normal control;
- wherein a creatine kinase enzymatic activity less than a normal control and a normal prostate specific antigen concentration is an indicator of prostate cancer.
Dependencies are inferred from the claim text.